1 / 16

Sixth Framework Programme Priority 1 Life Sciences, Genomics and Biotechnology for Health

InGenious HyperCare. Sixth Framework Programme Priority 1 Life Sciences, Genomics and Biotechnology for Health Fourth Call LSH - 2005 - 2.1.1-2 Hypertension and cardiovascular disease -

guri
Download Presentation

Sixth Framework Programme Priority 1 Life Sciences, Genomics and Biotechnology for Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. InGenious HyperCare Sixth Framework Programme Priority 1 Life Sciences, Genomics and Biotechnology for Health Fourth Call LSH - 2005 - 2.1.1-2 Hypertension and cardiovascular disease - Network of Excellence. The project should lead to the integration of research teams working on genetics, functional genomics and molecular mechanisms of hypertension and hypertension-related cardiac and vascular damage

  2. Mortality due to Leading Global Risk Factors (WHO World Health Report 2002) 8000 7000 High-mortality, developing region Lower-mortality, developing region Developed region 6000 5000 Attributable mortality (x 1000) 4000 3000 2000 1000 0 High BP High Chol. Unsafe sex High BMI Alcohol Indoor smoke solid fuels Urban air pollution Vit. A deficiency Occup. airborne particulates Lead exposure Tobacco Underweight Low fruit and veg. intake Physical inactivity Unsafe water, sanitation, and hygiene Iron deficiency Zinc deficiency Unsafe health-care injections Occup. risk factors for injury Illicit drugs Ezzati et al., Lancet 2002 0877 Z

  3. Number of People with Hypertension Aged 20 Years and Older by World Region and Sex in 2000 and 2025 2000 123.3 116.2 98.5 83.1 60.0 60.4 57.8 54.3 52.5 41.6 40.6 38.4 38.2 37.9 35.9 972 million (333 + 639) 33.0 Number of people with hypertension (millions) 161.8 2025 151.7 147.9 147.5 107.3 106.2 102.1 98.5 80.4 77.1 73.6 72.2 67.3 62.1 59.7 44.0 1.56 billion Established market countries Former socialist economies India Latin America and the Caribbean Middle eastern crescent China Other Asia and islands Sub- Saharian Africa Overall (developed + developing countries) Kearney et al Lancet 2005;365:217-23 1279 Z

  4. InGenious HyperCare Network of Excellence Integrating Genomics, Clinical Research and Care in Hypertension InGenious HyperCare

  5. InGenious HyperCare : Partners InGenious HyperCare Italy 1. Ist. Auxologico It., Milan (A. Zanchetti) 2. Un. Milano Bicocca (G. Mancia) 3. Un. Milano (D. Cusi, F. Magrini) 4. Un. Brescia (E. Agabiti-Rosei) 5. Un. Roma-Sapienza (M. Volpe) 6. Un. Padova (E. Casiglia) 7. Un. Vita Salute, Milano (G. Bianchi) France 8. INSERM Paris (S. Laurent) 9. CHU Nancy (F. Zannad) United Kingdom 10. Un. Glasgow (A. Dominiczak) 11. Un. Manchester (A. Heagerty) 12. Un. Leicester (B. Williams) Belgium 13. KU Leuven (J. Staessen) Netherlands 14. Un. Maastricht (H. Struijker-Boudier) Germany 15. Charité, Berlin (T. Unger, F. Luft) 16. MH Hannover (H. Haller) 17. WWU Münster (E. Brand) Spain 18. HCU Valencia (J. Redón) 19. FIMA Navarra (J. Diez) 20. Hosp. 12 Octubre, Madrid (L. Ruilope) 21. HCP Barcelona (A. Coca) Sweden 22. Un. Lund (O. Melander) Finland 23. Un. Helsinki (S. Tuomilehto) Poland 24. Med. Un. Gdansk (K. Narkiewicz) 25. Jagellonian Med. Un. Cracow (K. Kawecka) Czech Rep. 26. IKEM, Prague (R. Cifkova) 27. Charles Un. Pilsen (J. Filipovsky) Switzerland 28. Un. Lausanne (M. Burnier) Russia 29. RAMS, Novosibirsk (Y. Nikitin) China 30. IH Shanghai (J. Wang) SME 31. Mosaiques (H. Mischak) 32. CF Consulting (C. Finocchiaro) 1473 Z

  6. InGenious HyperCare Steering Committee Alberto Zanchetti (Network Coordinator) Javier Diez, Anna Dominiczak, Hermann Haller, Kalina Kawecka-Jaszcz, Giuseppe Mancia, Josep Redón, Jan Staessen, Faiez Zannad

  7. Hypertension and, more broadly, common cardiovascular diseases are due to complex interactions between environment and genetic background. This genetic background is also very complex, does not depend on alterations in single genes (except in rare cases), but on interactions between polymorphisms in a large number of genes, most of which are still unknown.

  8. Progress depends on concentrated efforts in orderTo study large numbers of subjects with different cv characteristics.To characterize subjects (phenotyping) in the most detailed and uniform way To approach the genetic background by exploring polymorphisms in multiple genes belonging to coherent pathophysiological pathways or families (mechanomics)

  9. InGenious HyperCare General Goals Integrating complementary but still fragmented experiences in Studying the physiological mechanisms of blood pressure control and hypertension development Phenotyping initiation and progression of organ damage Exploring genetics, genomics and proteomics of proneness to hypertension and hypertension-related cardiovascular disease

  10. InGenious HyperCare Specific Goals To create large common databases of subjects with and without hypertension, with and without hypertension-related cardiovascular and renal disease To establish joint platforms for phenotyping, genotyping, proteomic studies and statistical analyses To initiate coordinated programmes of research activities

  11. InGenious HyperCare Joint Research Packages A : Mechanomics of Hypertension The first group of JRPs (A1,A2,A3) proposed as joint research activity of the Network aims at identifying genetic, genomic and proteomic markers of disturbances in the major physiological mechanisms controlling blood pressure, as potential indicators of the risk of becoming hypertensive, thus indentifying those subjects genetically prone to hypertension upon whom to concentrate preventive measures A1. Genetics and Genomics of Autonomic Cardiovascular Control ( Coordinators G. Mancia and A. Zanchetti ) A2. Genetics, Genomics and Proteomics of Oxidative Stress and Inflammation ( Coordinators A. Dominiczak and H. Haller ) A3. Genetics and Genomics of Sodium Homeostasis in Hypertension and LVH ( Coordinators J. Staessen and K. Kawecka-Jaszcz )

  12. InGenious HyperCare Joint Research Packages B: Mechanomics of Hypertension - Related Cardiovascular Disease The second group of JRPs (B1, B2, B3) aims at jointly approaching the indentification of the genetic, genomic and proteomic markers of the risk of a hypertensive patient to develop a specific type of event (stroke, renal disease, heart failure), thus identifying those subjects in greatest need of therapeutic intervention. B1. Genetics and Genomics of Hypertension and Stroke (Coordinators A. Dominiczak and A. Zanchetti ) B2. Genetics, Genomics and Proteomics of Hypertension Associated with Renal Disease (Coordinators H. Hallerand J. Redón) B3. Genetics, Genomics and Proteomics of Heart Failure in Hypertension (Coordinators J. Diez and F. Zannad)

  13. InGenious HyperCare Spreading of Excellence ESH Advisory Board Ettore Ambrosioni (Bologna), Serap Erdine (Istanbul), Jean-Michel Mallion (Grenoble), Athanasios Manolis (Athens), Peter van Zwieten (Amsterdam) Spreading of Excellence Committee Giuseppe Mancia (Milano), José Rodicio (Madrid), Sverre Kjedsen (Oslo), Anthony Haegerty (Manchester), Kalina Kawecka-Jaszcz (Cracow), Renata Cifkova (Prague), Carla Finocchiaro (Milano)

  14. InGenious HyperCare Spreading of Excellence Activities Training Annual teaching courses in cooperation with ESH, also open to interested investigators outside the Network Involvement of doctoral students : 30 doctoral students already listed in the proposal, but more to be involved through academic partners of the Network Dissemination Contacts , through ESH, with national hypertension societies Updating of Network activities at annual meetings of ESH Yearly workshops, preferentially colocated with annual ESH meetings, ESH Summer Schools

  15. The Network research activities include genetic research in some large existing cohorts or populations, but are also centered on prospective studies on subjects and, particulary, families which should be recruited on the basis of detailed protocols requiring precise phenotyping.As precise phenotyping is a prerequisite for genotyping, the Steering Committee has thought that this first ESH Satellite Symposium of InGenious HyperCare should be centered on phenotyping.

  16. Integrating Genomics, Clinical Research and Care in HypertensionThe InGenious HyperCare European NetworkProgramme Zanchetti (Milan): InGenious HyperCare - Plans and progresses T. Kuznetsova (Leuven): Excellence in phenotyping - Assessment of left ventricular function J. Diez (Pamplona): Excellence in phenotyping - Circulating markers of left ventricular dysfunction J. Redon (Valencia): Excellence in phenotyping - Renal function and microalbuminuria A. Dominiczak (Glagow): Genome scans in complex traits: is hypertension a special case?

More Related